{"id":"jkn2401-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JKN2401 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, leading to reduced postprandial glucose excursions and improved overall glycemic control in patients with type 2 diabetes.","oneSentence":"JKN2401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:45.897Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07440524","phase":"PHASE2","title":"A Phase 2 Trial of JKN24011 in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-01","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":215},{"nctId":"NCT07330310","phase":"PHASE3","title":"A Phase 3 Trial of JKN2401 Injection in COPD","status":"NOT_YET_RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2026-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":888}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JKN2401 Injection","genericName":"JKN2401 Injection","companyName":"Joincare Pharmaceutical Group Industry Co., Ltd","companyId":"joincare-pharmaceutical-group-industry-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"JKN2401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}